RecruitingPhase 1NCT07383506

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations

Sponsor

Cogent Biosciences, Inc.

Enrollment

90 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Endometrial Cancer HER2-low Breast Cancer HR Positive/HER-2 Negative Breast Cancer PIK3CA Mutations Advanced Solid Tumors, Adult

Summary

This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA mutations

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CGT6297 for people with advanced solid tumors, adult, endometrial cancer, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.